KRAS and lung carcinoma: In the case of MTZ, one study showed its anti-tumor effects in lung cancer cells, where it was identified to be selectively effective against KRAS-mutant lung cancer cells, as compared to wild-type cells, in screening tests carried out using 1271 small molecules; the selectivity of MTZ was more obvious than that of other benzimidazoles [39].